Streetbeat News

Revenues

SPY

TSLA

The article covers a wide range of topics from the crypto market's recovery, with Bitcoin touching $70K and Ethereum and Dogecoin also bouncing upward, to various US and world political and economic news. It mentions Tesla's rollout of a free Full Self-Driving trial in the US, the London Stock Exchange's significant bet on Bitcoin and Ether, and predictions of stock market rallies by Goldman Sachs and Bank of America. Additionally, it touches on tech news including antitrust lawsuits against major companies, AI developments, and electric vehicle updates, including debates on Tesla's EVs versus hybrids.

Portfolio Pulse from Akanksha Bakshi

March 26, 2024 | 1:23 pm

HSY

MDLZ

NVDA

Cocoa prices have surged to $10,000 per metric ton, doubling in just 50 days, due to weather and disease impacting crops in West Africa. Hershey Co (HSY) and Mondelez International Inc (MDLZ) have warned of the impact on their earnings, with Hershey expecting limited earnings growth this year. The situation has led to 'shrinkflation' for consumers, with chocolate products becoming smaller and more expensive. Nvidia Corporation (NVDA) is mentioned for comparison, having added $1 trillion to its market cap in 67 days of 2024.

Portfolio Pulse from Neil Dennis

March 26, 2024 | 1:19 pm

VIRI

Virios Therapeutics, Inc. (NASDAQ:VIRI) announced the publication of an international patent for IMC-2, aimed at treating Long-COVID (LC) symptoms. The patent, published by the World Intellectual Property Organization, covers the use of a combination of valacyclovir and celecoxib for treating LC, including fatigue and cognitive dysfunction. Preliminary studies show significant reductions in LC symptoms, with further results expected from an ongoing trial. The potential market includes over 45 million adults in the US, highlighting a significant need for effective LC treatments.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:17 pm

KEN

Kenon Holdings reported a FY23 revenue of $692M for its subsidiary OPC, up from $574M in FY22. The increase is attributed to higher electricity sales in Israel and the U.S., and the commencement of operations at Tzomet and Gat Power Plants. Despite the revenue growth, profit for the period decreased to $47M from $65M, with a notable rise in cost of sales and finance expenses. Adjusted EBITDA also saw a significant increase from $250M to $304M.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:16 pm

CELH

Celsius Holdings, Inc. (NASDAQ:CELH), the maker of CELSIUS® energy drinks, announced its expansion into Australia and New Zealand through a definitive manufacturing, sales, and distribution agreement with Suntory Oceania. This move is part of CELSIUS's strategy to grow its global sales and distribution footprint, targeting strategically important energy drink markets. The company expects to start sales in these new markets in Q4 2024, aiming to accelerate growth in 2025.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:13 pm

CELU

Celularity Inc. (NASDAQ:CELU) announced that its product Biovance 3L received a Healthcare Common Procedure Coding System (HCPCS) Q code approval from the U.S. Centers for Medicare & Medicaid Services (CMS), effective April 1, 2024. Biovance 3L is a tri-layer allograft derived from placental tissue for wound treatment. This approval is expected to drive growth and impact Celularity's performance positively.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 1:02 pm

SAGE

Sage Therapeutics (NASDAQ:SAGE) has been reviewed by 5 analysts in the last three months, showing diverse opinions from bullish to bearish. The recent evaluations indicate a shift towards a more positive outlook, with an average 12-month price target of $26.2, up 16.44% from the previous $22.50. Analysts from JP Morgan, RBC Capital, Morgan Stanley, and HC Wainwright & Co. have adjusted their ratings and price targets, reflecting changing market dynamics and company performance. Sage Therapeutics, a clinical-stage biopharmaceutical company, has shown significant revenue growth of 2621.54% as of December 31, 2023, and has a strong financial health with impressive ROE and ROA figures.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 1:00 pm

CSR

Analysts have mixed views on Center (NYSE:CSR), with recent evaluations showing a shift towards a more neutral stance. The average 12-month price target is $62.00, indicating a 4.5% increase from the previous target. Center, a REIT focusing on apartment communities, faces challenges with a -5.57% revenue decline and a net margin of -15.24%, but has a strong ROE of -1.55% and a prudent debt management strategy.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 1:00 pm

LNW

In the past three months, 8 analysts have provided diverse ratings for Light & Wonder (NASDAQ:LNW), with a recent shift towards more bullish sentiments. The average 12-month price target has risen to $104.5, marking a 7.73% increase from the previous target. Light & Wonder, a major player in electronic gaming and mobile games, has shown notable financial performance with a 13.05% revenue growth, impressive net margin, ROE, and ROA, despite a high debt-to-equity ratio.

Portfolio Pulse from Benzinga Insights

March 26, 2024 | 1:00 pm

SPY

The latest USA Redbook data shows a year-over-year increase of 3.9%, up from the previous 3.4%.

Portfolio Pulse from Benzinga Newsdesk

March 26, 2024 | 12:55 pm